湖南启元律师事务所 关于启迪药业集团股份公司 2025年第三次临时股东会的 法律意见书 湖南省长沙市芙蓉区建湘路 393 号世茂环球金融中心 63 层 410000 根据中国证监会发布的《上市公司股东会规则》第六条的有关规定，现出具法 律意见如下： 电话：（0731）82953778 传真：（0731）82953779 网站：www.qiyuan.com 致：启迪药业集团股份公司 湖南启元律师事务所接受启迪药业集团股份公司（以下简称"公司"）的委托， 指派本所律师出席了公司 2025 年第三次临时股东会（以下简称"本次股东会"）， 对会议进行现场律师见证，并出具法律意见书。 本所出具本法律意见基于公司已作出如下承诺：所有提供给本所律师的文件的 正本以及经本所律师查验与正本保持一致的副本均为真实、完整、可靠。 为出具法律意见，我们依法审核了公司提供的下列资料： 1、刊登在中国证券监督管理委员会（以下简称"中国证监会"）指定媒体报纸 和巨潮资讯网（http://www.cninfo.com.cn/）上的关于召开 2025 年第三次临时股东会 的通知公告； 2、本次股东会股权登记日的公司股东名册、出席现场会议的股东 ...

证券代码：000590 证券简称：启迪药业 公告编号：2025-060 启迪药业集团股份公司 2025年第三次临时股东会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 假记载、误导性陈述或重大遗漏。 记载、误导性陈述或重大遗漏。 特别提示 1、本次会议未出现否决提案的情形。 2、本次股东会未涉及变更以往股东会已通过的决议。 一、会议召开的情况 1、召开时间： （1）现场会议时间：2025 年 12 月 16 日(星期二)下午 14:30。 （2）网络投票时间：2025 年 12 月 16 日。其中，通过深圳证券交易所交易 系统进行网络投票的时间为 2025 年 12 月 16 日上午 9:15—9:25,9:30—11:30 和下 午 13:00-15:00；通过深圳证券交易所互联网投票系统进行网络投票的时间为 2025 年 12 月 16 日上午 9:15 至下午 15:00 期间的任意时间。 2、现场会议召开地点：湖南省衡阳市雁峰区罗金桥 1 号（雁峰区工业项目 集聚区）古汉中药有限公司一楼会议室。 3、召开方 ...

Investment Rating - The report does not explicitly state an investment rating for the industry [2] Core Views - The pharmaceutical and biotechnology sector saw a weekly increase of 2.67%, underperforming the Wind All A index (2.9%) but outperforming the CSI 300 index (1.64%). The raw material drug sector experienced a decline of 4.27%, while chemical preparations and pharmaceutical circulation products increased by 4.18% and 3.71%, respectively [3][8] - Recent policies in Shanghai and Beijing aim to support the high-quality development of the medical device industry, indicating a shift towards innovation and global competitiveness in this sector. The report suggests monitoring the transformation progress of leading companies in the medical device field [3][12] - Flu activity is on the rise, with the percentage of flu-like cases reported by sentinel hospitals in southern provinces reaching 7.8%, up from 6.8% the previous week, and higher than the same period in 2022 and 2024 [3][11] Summary by Sections Market Weekly Review - The pharmaceutical and biotechnology sector increased by 2.67% from November 24 to November 28, 2025, with raw material drugs declining by 4.27% and chemical preparations increasing by 4.18% [8][9] - Individual stock performances included significant gains for Haiwang Biological (38.2%), Yue Wannianqing (36.2%), and Guangji Pharmaceutical (31.7%), while *ST Changyao (-15.3%), Huitai Medical (-9.6%), and Kangwei Century (-8.8%) saw notable declines [11] Industry News and Key Company Announcements Important Industry Events - The report highlights the increase in flu-like illness percentages in both southern (7.8%) and northern (8.6%) provinces, indicating a significant rise in flu activity compared to previous years [11][12] Industry News - Significant approvals were noted, including the NMPA's approval of Xinmeiyue® for treating moderate to severe plaque psoriasis and the FDA's accelerated approval of Sibeprenlimab for IgAN treatment [12][14] Company Announcements - Notable announcements include the FDA approval of a generic injectable drug by Jianyou Co. and the successful completion of a Phase III trial for JS001sc, a subcutaneous PD-1 monoclonal antibody for non-small cell lung cancer [15][16]

Investment Rating - The industry rating is maintained at "Overweight" [8] Core Views - The market performance of the traditional Chinese medicine (TCM) sector showed a slight increase of 1.29%, which is the smallest among secondary sub-sectors [1] - The price governance of Chinese patent medicines is being actively implemented across multiple regions, aiming to create a unified and competitive drug market [4][5] - The valuation metrics for the TCM sector indicate a PE (ttm) of 27.72X and a PB (lf) of 2.33X, with both metrics showing slight increases compared to the previous week [2] Market Performance - The TCM sector reported a market index of 6501.99 points, reflecting a 1.29% increase over the last week [1] - The overall pharmaceutical and biological sector index rose to 8430.03 points, with a 2.67% increase [1] Valuation Metrics - The TCM sector's PE (ttm) is at 27.72X, up by 0.36X week-on-week, with a one-year maximum of 30.26X and a minimum of 24.72X [2] - The PB (lf) stands at 2.33X, increasing by 0.02X from the previous week, with a one-year maximum of 2.54X and a minimum of 2.17X [2] Supply Chain Insights - The market for TCM raw materials has shown signs of recovery, with a price index of 225.55 points, reflecting a 0.4% increase from the previous week [3] - The market sentiment for TCM raw materials is improving, with increased foot traffic and positive investment sentiment [3] Policy and Regulatory Environment - Multiple regions have initiated price governance for Chinese patent medicines, focusing on high-priced products with significant price discrepancies [4][5] - The ongoing supply-side reforms are expected to reshape competitive factors within the industry, with a shift from channel-driven to value and cost-driven competition [5] Investment Recommendations - The report suggests focusing on three main investment themes: price governance, consumption recovery, and state-owned enterprise reform [11] - Specific recommendations include companies with strong R&D capabilities, unique products, and those less affected by centralized procurement [12]

Group 1 - The Chinese medicine sector experienced a decline of 0.83% on November 28, with Yue Wannianqing leading the drop [1] - The Shanghai Composite Index closed at 3888.6, up 0.34%, while the Shenzhen Component Index closed at 12984.08, up 0.85% [1] - Key stocks in the Chinese medicine sector showed mixed performance, with Tai Long Pharmaceutical rising by 5.37% to a closing price of 8.04 [1] Group 2 - Yue Wannianqing saw a significant drop of 13.71%, closing at 22.84, with a trading volume of 296,100 shares [2] - Other notable declines included Zhongsheng Pharmaceutical, which fell by 10.00% to 23.95, and Te Yi Pharmaceutical, which decreased by 6.41% to 14.01 [2] - The overall net capital flow in the Chinese medicine sector indicated a net outflow of 981 million yuan from main funds, while retail investors contributed a net inflow of 766 million yuan [2]

Core Viewpoint - Qidi Pharmaceutical is currently not directly operating elderly care service institutions but is engaging with the elderly care industry through products, diagnostic services, and health tourism services [1] Group 1: Business Operations - The company has a complete product matrix addressing the chronic disease management and daily health needs of the elderly, including exclusive traditional Chinese medicines and health food products [1] - The established Guhang Traditional Chinese Medicine Industrial Park serves as a national 3A industrial tourism site, integrating intelligent manufacturing, cultural education, and health care experiences [1] Group 2: Financial Performance - For the period from January to September 2025, the company achieved a revenue of 225 million yuan, representing a year-on-year growth of 3.97% [1] - The net loss for the same period was 15 million yuan, with a year-on-year reduction in losses of 47.91% [1]

Core Viewpoint - The company intends to change its name to "Gu Han Pharmaceutical Group Co., Ltd." and amend its articles of association accordingly [1] Group 1 - The board of directors has approved the proposal for the name change [1] - The company will apply for a change in its stock abbreviation with the Shenzhen Stock Exchange after the name change is completed [1]

Core Viewpoint - The company intends to change its name to "Gu Han Pharmaceutical Group Co., Ltd." and amend its articles of association accordingly [1] Group 1 - The board of directors has approved the proposal for the name change [1] - The company will apply for a change in its stock abbreviation with the Shenzhen Stock Exchange after the name change is completed [1]

每经AI快讯，启迪药业（SZ 000590，收盘价：11.45元）11月26日晚间发布公告称，公司第十届董事会 临时会议于2025年11月25日以现场与通讯相结合方式召开。会议审议了《关于补选公司董事会战略委员 会委员的议案》等文件。 每经头条（nbdtoutiao）——国开行辟谣的"人民资产"是什么？记者实探：号称投资600元80天赚8万 元！一位投资人的女儿：劝不住她，警察都拦不住 2025年1至6月份，启迪药业的营业收入构成为：中药及保健品占比94.02%，其他占比5.98%。 （记者 胡玲） 截至发稿，启迪药业市值为27亿元。 ...

证券代码：000590 证券简称：启迪药业 公告编号：2025-058 启迪药业集团股份公司 关于拟变更公司名称并修订《公司章程》的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 假记载、误导性陈述或重大遗漏。 记载、误导性陈述或重大遗漏。 2、该事项尚需经公司股东会审议通过，并向市场监督管理部门申请变更登 记 一、公司名称拟变更基本情况 （一）拟变更公司名称情况 启迪药业集团股份公司（以下简称"公司"）于 2025 年 11 月 25 日召开第十 届董事会临时会议，审议通过了《关于拟变更公司名称并修订<公司章程>的议 案》，同意将公司名称拟变更为"古汉医药集团股份公司"，并同步修订《公司章 程》的相关条款。待公司名称变更完成后，公司将根据深圳证券交易所有关规定 向其申请变更证券简称，公司证券代码保持不变。 上述议案尚需提交公司股东会审议，同时提请股东会授权公司董事会指定专 人负责办理与本次变更公司名称及修订《公司章程》相关的工商变更登记、备案 等手续，及与更名相关的其他事项。 | 条款目录 | 现行公司章程 | | ...